Is a negative prostate biopsy a risk factor for a prostate cancer related death?
Menée à partir de données danoises portant sur 63 454 patients avec suspicion de cancer de la prostate et ayant subi une première biopsie transrectale de la prostate guidée par échographie, cette étude estime, en fonction du niveau sérique du PSA et des résultats de la biopsie (négatif ou positif), le taux cumulé de décès par cancer de la prostate et le taux cumulé de décès toutes causes confondues à 20 ans
About 30 years ago, Thomas Stamey persuaded urologists to abandon a diagnostic approach to prostate cancer that was predicated on measurable disease to one that was not.1 The new and apparently better approach was a semi-random interrogation of the prostate—otherwise known as transrectal biopsy, most often triggered by a raised prostate-specific antigen (PSA) measurement. Urologists have never been entirely comfortable with the PSA plus biopsy approach as a risk-stratification method. The number of needle deployments has increased with time to overcome the high rate of sampling error.
The Lancet Oncology , commentaire, 2016